UCSB Biologists Explain Why Antibiotics Fail

Article

When a patient is prescribed the wrong antibiotic to treat a bacterial infection, it's not necessarily the physician who is at fault. The current antibiotic assay -- standardized in 1961 by the World Health Organization and used worldwide -- is potentially flawed. So says UC Santa Barbara biologist Michael Mahan, whose lab has developed a new antimicrobial susceptibility test that could transform the way antibiotics are developed, tested and prescribed.

Drug testing often excludes potent antibiotics for the treatment of microbial infections (blue plates). Drug testing under conditions that mimic natural infections succeeds in identifying effective antibiotics (red plates), even though these same antibiotics failed standard tests. Courtesy of Peter Allen
 

When a patient is prescribed the wrong antibiotic to treat a bacterial infection, it's not necessarily the physician who is at fault. The current antibiotic assay -- standardized in 1961 by the World Health Organization and used worldwide -- is potentially flawed. So says UC Santa Barbara biologist Michael Mahan, whose lab has developed a new antimicrobial susceptibility test that could transform the way antibiotics are developed, tested and prescribed.

The standard test specifies how well drugs kill bacteria on petri plates containing Mueller-Hinton Broth, a nutrient-rich laboratory medium that fails to reproduce most aspects of a natural infection. Now, Mahan and colleagues have used a mouse model to demonstrate that a variety of antibiotics work differently against various pathogens when inside the mammalian body. Their findings appear in the journal EBioMedicine.

"The message is simple: Physicians may be relying on the wrong test for identifying antibiotics to treat infections," said Mahan, a professor in UCSB's Department of Molecular, Cellular and Developmental Biology. "By developing a test that mimics conditions in the body, we have identified antibiotics that effectively treat infections caused by diverse bacteria, including MRSA, the cause of deadly Staphylococcal infections. These drugs have been overlooked because they failed the standard tests, despite being inexpensive, nontoxic and available at local pharmacies."

Study authors are Michael Mahan, Lucien Barnes, Geneva Tripp and Douglas Heithoff. Courtesy of Sonia Fernandez

The research has significant implications for public health. If a drug that passed the standard test doesn't work, physicians can now choose a different drug immediately rather than increase the dose of the same drug when patients return -- often in worse condition -- after an ineffective first course of treatment.

Reliance on the standard test may have contributed to the rise in multidrug-resistant bacteria, Mahan noted, due to the continued prescription of ineffective antibiotics. Further, he added, the standard test may also be slowing the discovery of new antibiotics. "These 'wonder drugs' may already exist but have been rejected by the standard test and are consequently not used in practice," Mahan said.

The scientists also report a way to "fix" the standard test to better predict how well antibiotics will treat infections: Simply add sodium bicarbonate. More commonly known as baking soda, this chemical is found in abundance in the body, where it helps to maintain precise blood pH. "Sodium bicarbonate makes the petri plates behave more like the body and increases the test's accuracy for assigning the appropriate antibiotic to treat infections," explained co-lead author Douglas Heithoff, a project scientist at UCSB's Center for Nanomedicine.

Mahan also points out that pharmaceutical companies could benefit from using the revised test to rescreen their collections of purified compounds that have failed the standard test. "There could be a treasure trove of compounds that have been shelved but could actually be quite effective against antibiotic-resistant strains," he said.

"Things aren't as gloomy as we thought," Mahan added. "We just have to be smart about it and change the way we're using the drugs we already have while we continue to search for new ones."

Source: University of California - Santa Barbara

Related Videos
Jill Holdsworth, MS, CIC, FAPIC, CRCST, NREMT, CHL
Jill Holdsworth, MS, CIC, FAPIC, CRCSR, NREMT, CHL, and Katie Belski, BSHCA, CRCST, CHL, CIS
Baby visiting a pediatric facility  (Adobe Stock 448959249 by Rawpixel.com)
Antimicrobial Resistance (Adobe Stock unknown)
Anne Meneghetti, MD, speaking with Infection Control Today
Patient Safety: Infection Control Today's Trending Topic for March
Infection Control Today® (ICT®) talks with John Kimsey, vice president of processing optimization and customer success for Steris.
Picture at AORN’s International Surgical Conference & Expo 2024
Infection Control Today and Contagion are collaborating for Rare Disease Month.
Related Content